Overall survival curve of benign versus malignant.

<p>Overall survival curve of benign versus malignant.</p

Histologic illustration of benign and malignant SFT.

<p>A: Benign SFT. The tumor shows a patternless architecture composed of spindle cells with hyalinized stroma and thin-walled branching vessels (H&E stain; x200 magnification). B: Benign SFT. The spindle tumor cells have vesicular nuclei without significant cytological atypia, mitosis, and necrosis (H&E stain; x400 magnification). C: Malignant SFT. The tumor has similar architecture; however, cells exhibit marked cytological atypia, including nuclear pleomorphism and increased mitotic activity (H&E stain; x200 magnification). D: Malignant SFT showing atypical mitotic tumor (H&E stain; x400 magnification).</p

Overall survival curve of entire cohort.

<p>Overall survival curve of entire cohort.</p

An outline of the chemotherapy types and how many patients received each.

<p>*Taxane based regimens used: Carboplatinum/Taxotere, gemcitabine/docetaxol or taxotere, docetaxol, paclitaxel</p><p>**TKIs used: Imatinib, Sunitinib</p><p>^†Experimental treatments used: GARFT inhibitor, anti-CD40 monoclonal antibody</p><p>^‡Other treatments used: Dacarbazine, pemetrexed, Rapamycin, doxorubicin/cisplatinum, adriamycin/carboplatinum, cytarabine, avastin, cisplatinum, doxorubicin/ifosfamide</p><p>Note: Four of the five patients with benign histology who received chemotherapy had large tumors and two had incomplete resections</p><p>An outline of the chemotherapy types and how many patients received each.</p

Point and interval estimation of the median overall survival and overall survival rates at 1, 3, and 5 years.

<p>*The upper bound is not estimable using the Kaplan-Meier product limit approach because of the large proportion of censoring (76.2%). Each hazard ratio is estimated based on univariable Cox regression.</p><p>NR = No Range</p><p>Point and interval estimation of the median overall survival and overall survival rates at 1, 3, and 5 years.</p

Frequency (percentage) or median (*interquartile range) of patient characteristics for benign, malignant, and the whole groups.

<p>CNS, central nervous system; HPF, high-power field. P < 0.05 indicates dependence between the characteristic and histological status.</p><p>Frequency (percentage) or median (*interquartile range) of patient characteristics for benign, malignant, and the whole groups.</p